Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

EHDN 2022 and Ehdn 2022 View overview page

5:08
PTC518: oral splicing modifier under investigation for the treatment of Huntington’s disease
Amy-Lee Bredlau et al. • 16 Sep 2022
3:35
Phase II PIOVT-HD trial of PTC518 in early Huntington’s disease
Amy-Lee Bredlau et al. • 16 Sep 2022
1:09
Monitoring children at risk for juvenile Huntington’s disease
Ferdinando Squitieri • 3 Oct 2022
1:12
Improving data collection in Juvenile Huntington’s disease
Ferdinando Squitieri • 3 Oct 2022
3:03
Pridopidine application beyond Huntington’s disease
Michael Hayden • 27 Sep 2022
5:38
PROOF-HD: Phase III trial of oral S1R agonist pridopidine for the treatment of Huntington’s disease
Michael Hayden • 27 Sep 2022
4:57
Huntingtin function in health and disease: axonal transport
Frederic Saudou • 20 Sep 2022
3:35
Symptoms of juvenile onset Huntington’s disease
Ferdinando Squitieri • 3 Oct 2022
2:06
Advancing mHTT as a biomarker in Huntington’s disease
Lauren Byrne • 23 Sep 2022
2:05
Tackling cognitive impairment in Huntington’s disease: a significant unmet need
Aaron Koenig • 22 Sep 2022
1:18
Does loss of wildtype huntingtin function contribute to Huntington’s disease?
Michael Hayden • 27 Sep 2022
1:56
Strategies to improve ASOs in Huntington’s disease
Patrick Weydt • 23 Sep 2022
2:21
Huntingtin lowering: what level of wildtype protein knockdown is safe?
Michael Hayden • 27 Sep 2022
2:03
Targeting dysregulated axonal transport in Huntington’s disease
Frederic Saudou • 20 Sep 2022
3:32
NfL as a potential biomarker for juvenile onset Huntington’s disease
Lauren Byrne • 23 Sep 2022
1:34
EHDN 2022 meeting highlights
Patrick Weydt • 23 Sep 2022
The content of VJNeurology is intended for healthcare professionals